Mucosolvan (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan, is a mucolytic presented as an oral formulation for oral use. It helps relieve productive cough associated with acute or chronic bronchitis, respiratory tract infections with thick mucus, and COPD exacerbations.

GNH USA supplies Mucosolvan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to global quality standards and provides regulatory documentation for import and distribution. Customers benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Mucosolvan (ambroxol) is used as a mucolytic to improve clearance of bronchial secretions in several respiratory conditions.

Acute bronchitis: facilitates removal of thick sputum, reduces cough frequency and improves patient comfort. Chronic bronchitis: improves mucus clearance, decreases airway obstruction and supports better ventilation. COPD exacerbations: lowers mucus viscosity, assists expectoration and may shorten the duration of acute worsening. Respiratory tract infections with thick mucus: aids in expectoration, alleviates congestion and supports faster recovery.

Ambroxol is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Taste alteration: a temporary bitter or metallic taste in the mouth. - Nausea: mild to moderate nausea after oral intake. - Abdominal discomfort: mild stomach pain or cramps. - Diarrhea: loose stools occurring shortly after dosing.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling or anaphylaxis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: abnormal liver function tests. - Blood dyscrasias: neutropenia or eosinophilia.

When using ambroxol, certain precautions should be observed to ensure safe and effective therapy. - Pregnancy: safety not established; use only if clearly needed and prescribed. - Breastfeeding: caution advised; monitor infant for possible effects. - Renal impairment: consider dose adjustment and monitor renal function. - Asthma: observe for bronchospasm, especially in severe cases. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Ambroxol may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Anticholinergic agents: may diminish mucolytic effect. - Cytotoxic chemotherapy: potential increase in toxicity. - MAO inhibitors: risk of adverse systemic reactions.

Moderate Interactions (Monitor Closely): - Beta‑agonists: possible additive bronchodilatory effect. - Other mucolytics: risk of excessive mucus thinning. - NSAIDs: may increase gastrointestinal irritation.